BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 8,159 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 14.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,541 shares of the medical instruments supplier’s stock after selling 8,159 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in West Pharmaceutical Services were worth $16,318,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in WST. Evoke Wealth LLC acquired a new stake in West Pharmaceutical Services in the 4th quarter valued at $7,770,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of West Pharmaceutical Services by 1.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock valued at $75,766,000 after acquiring an additional 2,759 shares during the last quarter. Vanguard Group Inc. raised its holdings in West Pharmaceutical Services by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after acquiring an additional 104,740 shares in the last quarter. Mizuho Markets Americas LLC boosted its position in West Pharmaceutical Services by 142.3% during the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock valued at $11,724,000 after purchasing an additional 17,399 shares during the last quarter. Finally, Hsbc Holdings PLC grew its stake in West Pharmaceutical Services by 39.8% in the fourth quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock valued at $48,750,000 after purchasing an additional 39,392 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Down 0.4 %

Shares of West Pharmaceutical Services stock traded down $1.16 on Friday, reaching $313.63. 583,091 shares of the company were exchanged, compared to its average volume of 559,549. The company has a market capitalization of $22.75 billion, a price-to-earnings ratio of 41.38, a PEG ratio of 10.79 and a beta of 1.00. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $415.73. The company has a 50-day moving average of $309.69 and a 200 day moving average of $343.81.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. During the same period last year, the company posted $2.11 earnings per share. The business’s revenue was down 6.9% compared to the same quarter last year. On average, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.44 earnings per share for the current year.

Insider Activity at West Pharmaceutical Services

In related news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at $946,030.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.